Phenobal 10%

Quick links to important sections

Phenobal 10%

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phenobal 10%

Property Description
Active ingredient Phenobarbital
Form Oral Solution (10% Concentration)
Pharmacological class Barbiturate Anticonvulsant
General purpose Seizure control (AED)
Origin Synthetic Compound

What Type of Medicine is Phenobal 10%?

Phenobal 10% is a pharmaceutical preparation containing the established active substance Phenobarbital, which is chemically defined as a synthetic compound derived from Barbituric acid. It is classified as an Antiepileptic Drug (AED) belonging to the Barbiturate drug class, a category broadly recognized for its efficacy as a Central Nervous System (CNS) depressant. Phenobarbital has a recognized role in treating epilepsy. This standing confirms the drug’s long-standing, established importance in providing seizure management.


Composition and Form: The 10% Oral Solution

The preparation is presented as an oral solution, a liquid formulation intended for the oral route of administration. The 10% concentration is a defining feature of this formulation, signifying ten grams of Phenobarbital dissolved or suspended per one hundred milliliters of the final product, typically utilizing an aqueous base. This liquid form is often utilized as it facilitates exceptionally precise dose titration, a process considered necessary for achieving optimal therapeutic levels, particularly in patient groups requiring fine adjustments. This form differentiates Phenobal 10% from solid formulations of the same active ingredient.


General Purpose of Phenobarbital

The general purpose of Phenobarbital is to elevate the seizure threshold and stabilize neuronal function, directly mitigating the occurrence of seizures. As an AED, the medication functions by calming overexcited nerve cells, thereby preventing the disorganized, rapid electrical signaling that defines a seizure event. This action delivers the essential benefit of providing effective, ongoing seizure control, which is fundamental to the long-term management of conditions like epilepsy.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. WHO Essential Medicines List

What side effects are possible with Phenobal 10%?

Possible Side Effects and Safety Information

Adverse reactions associated with Phenobal 10% are classified in regulatory documents primarily by frequency and the body system affected. The official safety profile is organized to reflect both common experiences and rare, serious concerns.


Adverse Reaction Scope

The most common effects listed include Central Nervous System (CNS) effects such as somnolence (drowsiness), sedation, ataxia (loss of coordination), and nystagmus (involuntary eye movement). These effects are often noted as being more likely at the start of treatment or following dose adjustments.

System-Organ Class (SOC) Examples of Documented Adverse Reactions
Nervous System Sedation, Ataxia, Cognitive impairment, Paradoxical excitement
Skin and Subcutaneous Hypersensitivity reactions, Severe rash (SJS/TEN)
Blood and Lymphatic Megaloblastic anemia (with long-term use)

Serious Safety Concerns and Specific Considerations

The regulatory profile identifies serious adverse reactions, which include the risk of Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Antiepileptic drugs, including this medication, carry a documented risk of increasing the occurrence of suicidal ideation and behavior.

Specific populations have unique safety considerations: Pediatric patients may experience paradoxical reactions like hyperactivity or excitement. Older adults may have an increased risk of sedation, confusion, and falls. The drug is contraindicated in patients with conditions like severe respiratory depression and severe hepatic impairment due to increased toxicity risks. Long-term exposure is associated with risks to bone health, such as osteomalacia.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Phenobal 10% (Phenobarbital) is a serious event that is documented in regulatory prescribing information, requiring immediate medical attention.

Documented Overdose Manifestations and Outcomes

Manifestations reflect the drug’s profound central nervous system (CNS) depressant activity. Documented signs include CNS depression (drowsiness, confusion), respiratory depression, hypotension, hypothermia, ataxia, and nystagmus. Severe outcomes following massive exposure can escalate to circulatory collapse, pulmonary edema, cardiac arrest, coma, and death.

When to Seek Immediate Medical Help

Immediate emergency assistance is required for suspected or confirmed overdose. Regulatory instructions explicitly state to call emergency services if the affected person has collapsed, has trouble breathing, or cannot be awakened. Contacting a certified Regional Poison Control Center for guidance is also recommended.

Official Supportive Measures

There is no specific antidote for Phenobarbital documented in the official labeling. Management focuses on symptomatic and supportive treatment, including protecting the airway and supporting ventilation. Measures to enhance drug clearance, such as repeat-dose activated charcoal or extracorporeal removal techniques (e.g., hemodialysis), may be considered.

Population-Specific Consideration

Official labeling notes that uremia, often associated with impaired renal function, may increase CNS sensitivity to the drug’s effects.

Therapeutic Uses of Phenobal 10%

Phenobal 10% may be part of symptomatic management, supporting patients across key therapeutic domains. The medication is commonly used to help with symptoms related to seizure activity and as a sedative.

It is relevant for easing symptom clusters that appear suddenly or intensify over time, particularly those involving symptoms of increased neurological or muscular activity and excessive physical tension. Phenobal 10% is used for managing symptoms related to seizure activity, acute apprehension, and disrupted sleep patterns.

“This symptomatic support supports patients during difficult episodes by easing distress during phases where agitation or apprehension are noticeable.”

The medication is considered relevant for conditions involving symptoms of increased neurological or muscular activity, which may be part of symptomatic management when functional stability is affected.


Quick Fact: Support for Symptoms Related to Heightened Activity Phenobal 10% is commonly used in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during periods of heightened tension or symptoms associated with acute or episodic changes.

Regulatory References

  1. NIH DailyMed service

Eligibility and Restrictions for Use

Who Can and Cannot Use Phenobal 10%

Eligibility for Phenobal 10% (Phenobarbital) is strictly determined by official regulatory documents, classifying patient populations into groups where use is permitted, restricted, or absolutely prohibited.

Contraindicated Populations (Must Not Use)

Population/Condition Restriction Classification
Barbiturate Hypersensitivity Absolute Contraindication
Acute Porphyrias Absolute Contraindication
Marked Impairment of Liver Function Absolute Contraindication
Severe Respiratory Depression Absolute Contraindication
Sleep Apnea Contraindication

Restricted and Conditional Use Populations

Population/Condition Regulatory Caution/Restriction
Pregnant Women Use Restricted (Category D)
Nursing Mothers Use Restricted (Caution Recommended)
Older Adults (Geriatric) Use with Caution (Lower doses needed; risk of confusion/falls)
Renal Impairment Use with Caution (Drug elimination consideration)
Mentally Depressed Patients Use with Caution (Suicidal potential risk)

The drug is typically used in adult and pediatric patients requiring seizure control, but specific cautions exist for children due to the reported risk of cognitive deficits or paradoxical excitement. The official profile strictly prohibits use based on functional limitations (liver, respiratory) and specific comorbidities (porphyria, sleep apnea).

What should I know about interactions with other medicines?

The interaction profile for Phenobarbital is structured by its documented effects on drug metabolism and the central nervous system. As a potent inducer of hepatic CYP enzymes (specifically CYP3A4, 2B, and 2C families), Phenobarbital may accelerate the clearance of many co-administered medicinal products. This pharmacokinetic effect can result in a reduction of the co-medication's therapeutic plasma concentrations and clinical effect.

Interaction Type Examples of Affected Medicines/Substances Regulatory Outcome
Metabolic Acceleration Oral Contraceptives, Coumarin Anticoagulants, Corticosteroids Reduced Efficacy / Therapeutic Failure Risk
Additive CNS Effects Opioid Analgesics, Benzodiazepines, Alcohol Increased Sedation / Respiratory Depression Risk

Co-administration is contraindicated with certain antiviral agents, including Voriconazole, Cobimetinib, and specific hepatitis C therapies (Elbasvir/Grazoprevir), due to the high risk of severely decreased plasma concentrations and therapeutic failure. Use is also prohibited in patients with acute alcohol intoxication exhibiting depressed vital signs. Furthermore, the herbal product St. John's Wort is officially documented to reduce the effect of Phenobarbital itself. For patients receiving Coumarin Anticoagulants, the regulatory labeling requires more frequent prothrombin determinations to account for potential changes in anticoagulant activity. The regulatory profile notes caution in patients with impaired hepatic function due to the potent enzyme induction.

Mechanism of Action

The compound primarily acts within the central nervous system by modulating inhibitory and excitatory neurotransmission. Its main action is as a positive allosteric modulator of the GABA A receptor complex. This binding site interaction enhances the affinity of GABA (gamma-aminobutyric acid), increasing the duration and frequency of chloride ion ( Cl^-) channel opening. This potentiated chloride influx induces neuronal hyperpolarization, which reduces the postsynaptic neuron's excitability. The drug also engages secondary mechanisms, including the inhibition of voltage-gated calcium ( Ca^2+) channels and, at certain concentrations, sodium ( Na^+) channels. This modification of cation flow limits the release of excitatory neurotransmitters such as glutamate. The resulting molecular cascade suppresses the overall influence of excitatory signaling, contributing to a reduced frequency of action potential generation within neuronal networks.

Dosage and Administration Information

How to use Phenobal 10%: Administration Guidelines

Phenobal 10% (Phenobarbital Oral Solution) is administered via the oral route. The dosing schedule and total daily quantity are determined by the intended therapeutic goal, with specific adjustments required for certain patient groups.


Dosing Ranges for Adults

Regimen Goal Total Daily Dose Range Frequency Pattern
Anticonvulsant Use 60 to 200 mg Once daily or in divided doses
Daytime Sedation 30 to 120 mg In 2 to 3 divided doses
Oral Hypnotic 100 to 200 mg Single dose, usually at night

The maximum dose recommended for sedation regimens should not exceed 400 mg during a 24-hour period.


Administration and Course Duration

The oral solution is characterized by a slow onset of action, typically one hour or longer. For optimal absorption, the medicine is administered well diluted or on an empty stomach. Effective administration involves the dosage being carefully and slowly adjusted based on individual requirements.

Treatment duration varies by use: anticonvulsant management is generally intended for long-term use, whereas hypnotic use is limited to short-term management (e.g., typically not more than two weeks).

Special Procedural Instruction

The drug must not be discontinued abruptly when used for seizure prevention, as a rapid reduction may precipitate status epilepticus. Furthermore, dosage reduction is indicated for older adults and patients with impaired renal function or hepatic disease.

Recent Clinical Evidence

Evidence for Use in Long-Term Seizure Control

Phenobal 10% (phenobarbital) was evaluated in research exploring the long-term patterns of various seizure types, particularly convulsive epilepsy and partial onset seizures. Researchers utilized Randomized Controlled Trials (RCTs) and long-term observational cohort studies to compare the medicine against other treatments evaluated in the research. These studies monitored outcomes related to seizure frequency, including the rate at which people achieved seizure-free status as a study endpoint.

The research describes patterns related to the stability of seizure frequency, reporting how symptoms evolved over time. The overall evidence base for this use is considered moderate, reflecting an established research area that includes older foundational studies with known methodological limitations compared to modern trials.

Evidence for Use in Acute Hyperexcitability

Phenobarbital was also evaluated in hospital-based research exploring short-term symptom changes related to acute Alcohol Withdrawal Syndrome (AWS), a condition characterized by periods of heightened symptoms. The research primarily utilized Systematic Reviews combining data from numerous smaller observational cohort studies.

Studies examined metrics related to resource use, such as Intensive Care Unit (ICU) admission rates and the monitoring of mechanical ventilation status. Findings show patterns related to symptom intensity and the length of time patients were monitored in hospital settings. The evidence for this acute use is also considered moderate, but certainty remains low due to reliance on observational data and the limited information on the oral solution formulation specifically.

Research Gaps and Unresolved Questions

Research on long-term effects are not fully established regarding all outcomes. For example, studies tracking neurodevelopmental and cognitive assessments in children show mixed findings and inconsistency. Furthermore, comparative evidence is lacking in the form of large, high-quality RCTs across all current indications.

Studies explored the medicine’s use in children (including neonates) and adults with severe acute symptoms, but data for other subgroups, such as older adults, remain insufficient. Overall, the evidence quality varies across studies, highlighting areas where more research is ongoing.

Key Studies & References

  1. PHENOBARBITAL ORAL SOLUTION, USP CIV - DailyMed (Official Labeling)

Frequently Asked Questions (FAQ)

Common questions about Phenobal 10% (FAQ)

Q: How long does it usually take for Phenobal 10% to start working for seizures?

According to official product information, the oral solution of Phenobal 10% has a slow onset of action.

It typically takes one hour or longer for the medicine to be absorbed and begin working in the body to help control seizures. Achieving the full therapeutic benefit often requires a period of careful dosage adjustment by a healthcare provider.


Q: What is the expected duration of action for one dose of Phenobal 10%?

Phenobarbital, the active ingredient in Phenobal 10%, is classified as a long-acting barbiturate.

Official prescribing information indicates that the effects of a single dose generally last for an extended period, typically ranging from 10 to 12 hours or potentially longer.


Q: What is the difference between Phenobal 10% and other common anti-seizure medications?

Phenobal 10% belongs to the barbiturate class and works primarily by enhancing the effects of GABA (a calming chemical) in the brain.

The classification indicates its general mechanism of action, which contributes to its overall profile of effects compared to other anti-seizure drug classes.


Q: Is Phenobal 10% still considered a common or first-line treatment?

Phenobarbital has a long-established role in managing epilepsy.

It is included on the World Health Organization's Model List of Essential Medicines, confirming its continued importance globally. Its use compared to newer drugs varies by specific seizure type and regional medical guidelines.


Q: Is it common to experience memory problems while taking Phenobal 10%?

The official safety profile for Phenobarbital lists cognitive impairment as a possible adverse reaction.

This broad term may include difficulties with concentration, learning, and memory problems, particularly with long-term use.


Q: Why does Phenobal 10% sometimes cause people to have slurred speech?

Phenobarbital is a central nervous system depressant, and one of its common side effects is ataxia, or a lack of coordination.

This lack of muscle coordination, along with other CNS effects like sedation, can potentially affect the muscles needed for clear speech, leading to slurred or slowed speaking patterns.


Q: Is there a risk of physical dependence with long-term use of Phenobal 10%?

Regulatory warnings state that tolerance, psychological, and physical dependence may occur with continuous use of Phenobarbital.

Because of this risk, official guidelines state that the medication must be withdrawn gradually under professional supervision to avoid serious withdrawal symptoms.


Q: Can I take Phenobal 10% if I also take a medication for anxiety or sleep?

Official prescribing information advises caution when Phenobal 10% is used with other medications that cause drowsiness, including certain drugs for anxiety or sleep.

Combining these can result in additive central nervous system (CNS) depressant effects, which increases the risk of excessive sedation and respiratory depression.


Q: What should I do if I feel more irritable or agitated after starting Phenobal 10%?

Regulatory safety information notes that some patients, particularly children, may experience a paradoxical reaction, such as increased restlessness, excitement, or irritability.

If you notice significant or concerning changes in your behavior or mood, it is important to contact a healthcare professional.


Q: Can Phenobal 10% affect my body’s levels of Vitamin D or folic acid?

Long-term use of Phenobarbital is associated with an increased risk of specific health issues, including megaloblastic anemia and osteomalacia (bone disease).

These conditions are linked to potential changes in levels of essential nutrients like folic acid and Vitamin D. Such risks often necessitate appropriate monitoring.


Q: What kind of blood tests are required when taking Phenobal 10% long-term?

Official regulatory documents emphasize the need for regular monitoring through appointments and laboratory tests during long-term treatment.

These tests often include monitoring the level of the drug in your blood (therapeutic drug concentration) and checking your liver function to ensure safety.


Q: What happens if I miss a dose of Phenobal 10%?

Regulatory sources generally advise against taking a double dose to compensate for a missed dose.

Due to the nature of this medicine and the risk of potentially provoking seizures, it is important to contact a healthcare professional for guidance if you miss a dose.


Q: Can Phenobal 10% cause a temporary lowering of blood pressure?

Yes, official adverse reaction reports list hypotension (low blood pressure) as a possible cardiovascular side effect.

Though primarily noted in specific contexts like intravenous use, this remains a documented potential adverse effect.


Q: Can Phenobal 10% cause stomach upset or constipation?

Official safety data for Phenobarbital lists several common gastrointestinal adverse reactions.

These documented effects in the regulatory profile include nausea, vomiting, and constipation.


Q: Is Phenobal 10% considered a generic or a brand name medication?

Phenobarbital is the established generic name for the active ingredient.

Phenobal 10% refers to a specific formulation—the 10% oral solution. Regulatory guidance emphasizes the importance of maintaining consistency when using any anti-seizure medication.


Q: Why is Phenobal sometimes spelled as phenobarbitone?

The difference is regional. Phenobarbitone is the official spelling of the active ingredient used in several countries, including the United Kingdom and Australia.

Phenobarbital is the spelling most commonly used in the United States and Canada, though both refer to the exact same chemical substance.


Q: How does Phenobal 10% affect the GABA receptors?

Phenobarbital works by affecting the brain's GABA A receptor, which helps control excitability in the nervous system.

It is a positive modulator, meaning it enhances the effect of GABA (the brain's primary calming chemical), causing chloride channels to stay open longer. This process reduces the overall excitability of nerve cells, which contributes to seizure control.


Q: Is there any research about Phenobal 10% and long-term cognitive effects?

Official warnings note the potential for cognitive impairment with long-term use of phenobarbital.

Research studies on long-term cognitive outcomes, particularly in children, have shown mixed and inconsistent findings, making it an area that requires continued monitoring and research.


Q: What is the half-life of Phenobal and why is it important for dosing?

Phenobarbital has an exceptionally long elimination half-life in adults, typically spanning several days.

This long duration means it takes a long time for the drug to be eliminated from the body, which is a factor in why it may be prescribed for once-daily dosing and why it takes a while to reach stable drug levels.


Q: Does Phenobal 10% affect the immune system or cause swollen lymph nodes?

Phenobarbital carries a documented, though rare, risk of causing Antiepileptic Hypersensitivity Syndrome (AHS).

This serious reaction can involve symptoms affecting multiple organ systems and may include signs like fever, rash, and lymphadenopathy (swollen lymph nodes).


Q: What does 'enzyme induction' mean regarding Phenobal 10% interactions?

Enzyme induction refers to the process where Phenobarbital significantly speeds up the activity of certain liver enzymes (primarily CYP enzymes).

This effect causes the body to break down and eliminate many other medications more quickly, which can lead to a reduction in the effectiveness of those other drugs.


Q: How does the drug's action compare to benzodiazepines?

Both drug classes are central nervous system depressants that act on the GABA A receptor.

However, Phenobarbital primarily increases the duration of the chloride channel opening, while benzodiazepines increase the frequency. Phenobarbital is generally associated with a higher risk of severe toxicity in the event of an overdose.


Q: Is it normal for a person's tolerance to Phenobal 10% to change over time?

Official warnings indicate that tolerance to the drug's effects can develop with continuous use.

This means that over time, changes may occur in the body's response, necessitating close monitoring by a healthcare professional.


Q: Is Phenobal 10% used for conditions other than epilepsy, like anxiety or insomnia?

Yes, in addition to its main use for seizure control, Phenobarbital has regulatory indications for other uses.

It is officially indicated for use as a sedative to manage daytime apprehensiveness and as an oral hypnotic for the short-term management of insomnia.


Q: Is it normal to feel tired or sedated every day while on Phenobal 10%?

While somnolence (drowsiness) and sedation are listed as the most common side effects, the official safety profile often notes these effects are more likely at the start of treatment or following a dose change.

Though these effects may persist for a time, they are not necessarily a constant throughout the entire course of long-term therapy.

How should Phenobal 10% be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal requirements for Phenobal 10% (Phenobarbital) are based on its classification as a Schedule IV Controlled Substance and a regulated hazardous waste.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from light and moisture.
Packaging Dispense in a tight, light-resistant container and keep the container tightly closed.
Security Keep out of the reach of children. The product must be stored locked up to prevent diversion.

Disposal Rules

Unused or expired product must be disposed of according to federal and local regulations for controlled substances and hazardous waste. Disposal must follow DEA guidelines for non-retrievable destruction. To protect the environment, the product should not be flushed down the toilet or placed in household trash, and release into drains or sewers is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Phenobal 10% found in:

A-Z Index: